Synthesis and Distribution of Drugs of Abuse and Related Compounds
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH NIDA
Contract Value
Not provided
Codes & Classification
Solicitation Number
75N98027R00006SB
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
AN11
Additional Details
The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC), has issued a Small Business Sources Sought Notice (Procurement Identifier: 75N98027R00006SB) to identify qualified small business organizations capable of supporting the synthesis and distribution of drugs of abuse and related compounds. This notice is intended solely for market research and information gathering purposes and does not constitute a solicitation for proposals, abstracts, or quotations.
**Purpose and Scope**
The primary objective of this procurement is to ensure the continued operation and enhancement of the NIDA Drug Supply Program, which plays a critical role in supporting substance use research. The program provides the research community with a diverse inventory of authentic, pure, controlled, and uncontrolled drugs, as well as other chemical compounds—both unlabeled and isotopically labeled (with deuterium, tritium, carbon-14, and iodine-125). These materials are essential for basic and applied research in the field of drug abuse.
The scope of work includes:
- Synthesis, acquisition, and maintenance of a wide range of drugs of abuse and related chemical substances, including both new and existing compounds.
- Distribution of these compounds to approved research investigators in accordance with NIDA guidelines.
- Regular analysis, testing, and documentation to ensure chemical purity (maintained at not less than 95%) and the generation of updated chemical data sheets.
- Replenishment of depleted inventory through synthesis or acquisition.
- Identification and incorporation of newly discovered compounds relevant to drug abuse research.
- Management and updating of the Drug Inventory Supply Control System (DISCS) database.
- Secure storage and safe shipment of all compounds, including those requiring refrigeration or special handling due to their physical state (e.g., solutions).
- Processing of researcher requests and maintaining compliance with all applicable regulations.
**Key Requirements and Deliverables**
Vendors must demonstrate the following capabilities:
- Ability to receive, store, and manage an inventory comprising hundreds of DEA-controlled and uncontrolled substances, including peptides and neuropeptides, in quantities of several kilograms.
- Provision of secure, DEA-compliant storage facilities, including refrigeration and specialized containment for solution-phase substances.
- Synthesis of a variety of chemical compounds, including but not limited to cannabinoids, hallucinogens, narcotics and antagonists, stimulants, depressants, and peptides, with the ability to produce both unlabeled and isotopically labeled variants.
- Maintenance of compound purity and re-purification processes as necessary.
- Possession of a DEA Research Registration for Schedules II to V, and the demonstrated capability to obtain registration for Schedule I controlled substances.
**Contracting Entity and Classification**
- Contracting Entity: National Institutes of Health (NIH), NIDA
- Department: U.S. Department of Health and Human Services
- NAICS Code: 541715 – Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Product Service Code: AN11
- Set-Aside: Small Business Administration (SBA) set-aside; only small businesses under the applicable NAICS code are eligible to respond.
**Submission Instructions and Contact Information**
Interested small businesses must submit a capability statement that clearly addresses their expertise, experience, and capacity to fulfill the outlined requirements. Submissions should include:
- Detailed descriptions of staff expertise, availability, and relevant training.
- Evidence of current capability and prior experience with similar projects.
- Corporate management experience and references from previous government contracts.
- Organization name, address, Unique Entity Identifier (UEI), and business size/type classification.
- Technical and administrative points of contact, including names, titles, addresses, phone numbers, and email addresses.
Responses must be submitted electronically in Microsoft Word or Adobe PDF format, limited to ten pages (excluding cover page, executive summary, resumes, and references), using standard formatting guidelines. All submissions must be sent to Contract Specialist Shaun Rostad at [email protected] by 1:00 p.m. EST on November 20, 2026. The subject line should reference the Sources Sought Number, UEI, and organization name. Paper or faxed submissions will not be accepted.
**Special Considerations**
- This notice is for information and planning purposes only; it does not obligate the Government to issue a solicitation or award a contract.
- Respondents should not include proprietary, classified, or sensitive information in their submissions.
- The Government reserves the right to use non-proprietary technical information provided in any resultant solicitation.
- Any future solicitation may be issued under a different solicitation number.
**Contact Information**
- Primary Contact: Shaun Rostad, [email protected]
- Secondary Contact: Joshua T. Lazarus, [email protected]
For further details and updates, interested parties should refer to the official notice on SAM.gov (Opportunity ID: 88a294155bb8437c814958fee64570c9).
This opportunity is ideal for small businesses with demonstrated expertise in the synthesis, storage, and distribution of controlled and uncontrolled substances for research purposes, and with the regulatory credentials necessary to handle DEA-scheduled compounds.